Compare ALT & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALT | OFIX |
|---|---|---|
| Founded | 1997 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 421.5M | 473.3M |
| IPO Year | 2005 | 1998 |
| Metric | ALT | OFIX |
|---|---|---|
| Price | $2.96 | $12.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $17.67 | $17.25 |
| AVG Volume (30 Days) | ★ 3.4M | 211.9K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 25.37 | ★ 29.39 |
| EPS | ★ N/A | N/A |
| Revenue | $41,000.00 | ★ $822,312,000.00 |
| Revenue This Year | N/A | $6.13 |
| Revenue Next Year | N/A | $6.22 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 105.00 | 2.85 |
| 52 Week Low | $2.80 | $10.25 |
| 52 Week High | $7.73 | $16.99 |
| Indicator | ALT | OFIX |
|---|---|---|
| Relative Strength Index (RSI) | 36.10 | 46.78 |
| Support Level | $2.87 | $10.94 |
| Resistance Level | $4.25 | $12.99 |
| Average True Range (ATR) | 0.17 | 0.40 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 17.26 | 38.89 |
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.